Global Erythropoietin Drugs Market Report and Forecast 2023-2031

Global Erythropoietin Drugs Market Report and Forecast 2023-2031


Global Erythropoietin Drugs Market Outlook

The global erythropoietin drugs market was valued at USD 10.3 billion in 2022, driven by the increasing prevalence of chronic kidney disease and the increasing incidence of cancer across the globe. The market size is anticipated to grow at a CAGR of 5.7% during the forecast period of 2023-2031 to achieve a value of USD 17 billion by 2031.

Erythropoietin Drugs: Introduction

Erythropoietin (EPO) drugs are a class of medications that stimulate the production of red blood cells in the body. These drugs are used primarily in the treatment of anemia, particularly in patients with chronic kidney disease, cancer, or undergoing certain medical procedures like chemotherapy or dialysis. EPO drugs mimic the action of natural erythropoietin, a hormone produced by the kidneys that regulates red blood cell production.

EPO drugs are administered either through injections or subcutaneous implants. They work by stimulating the bone marrow to produce more red blood cells, which helps improve oxygen-carrying capacity and alleviate symptoms associated with anemia.

Key Trends in the Erythropoietin Drugs Market

Some key trends involved in the erythropoietin drugs market are as follows:
  • Rising Prevalence of Chronic Kidney Disease (CKD): The increasing prevalence of CKD, driven by factors such as aging population, diabetes, and hypertension, is a major driver for the growth of the EPO drugs market. CKD often leads to anemia, and EPO drugs are an important treatment option to manage anemia in these patients.
  • Growing Use in Oncology: EPO drugs are widely used in the field of oncology to manage anemia associated with chemotherapy and cancer-related conditions. As the incidence of cancer continues to rise globally, the demand for EPO drugs in cancer care is expected to increase.
  • Advancements in Drug Delivery Systems: The development of new drug delivery systems, such as long-acting EPO formulations and sustained-release implants, is a key trend in the EPO drugs market. These advancements aim to enhance patient convenience and adherence by reducing the frequency of drug administration.
  • Biosimilars and Patent Expirations: The market for EPO drugs has witnessed the entry of biosimilars, which are highly similar versions of the original EPO drugs. The availability of biosimilars has increased competition and led to cost savings for healthcare systems. Additionally, the expiration of patents for some originator EPO drugs has further contributed to market growth.
Erythropoietin Drugs Market Segmentations

Market Breakup by Drug Type
  • Biologics
  • Biosimilars
Market Breakup by Product Type
  • Epoetin-alfa
  • Epoetin-beta
  • Darbepoetin-alfa
  • Others
Market Breakup by Application
  • Haematology
  • Kidney Disorder
  • Cancer
  • Others
Market Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Erythropoietin Drugs Market Scenario

The Erythropoietin (EPO) drugs market is a vital segment of the pharmaceutical industry that focuses on the development and distribution of medications aimed at stimulating red blood cell production. EPO drugs play a crucial role in managing anaemia, particularly in patients with chronic kidney disease, cancer, or undergoing certain medical procedures like chemotherapy or dialysis.

The market for EPO drugs is driven by several factors, including the rising prevalence of chronic kidney disease and the increasing incidence of cancer globally. The aging population, diabetes, and hypertension are contributing to the growing prevalence of chronic kidney disease, leading to a higher demand for EPO drugs. Additionally, the use of EPO drugs in oncology has expanded significantly as they help manage anaemia associated with cancer and its treatments.

Advancements in drug delivery systems have also been a key driver in the market. The development of long-acting EPO formulations and sustained-release implants has improved patient convenience and compliance by reducing the frequency of drug administration.

In summary, the EPO drugs market is driven by factors such as the rising prevalence of chronic kidney disease and the increasing use of EPO drugs in oncology. Advancements in drug delivery systems, the entry of biosimilars, and regulatory compliance are key trends shaping the market. As the demand for effective anaemia management continues to rise, the market for EPO drugs is expected to grow further, driven by innovation and adherence to regulatory requirements.

Erythropoietin Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Amgen Inc.
  • Biocon Limited
  • Dr. Reddy’s Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • LG Chem Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Erythropoietin Drugs Market Overview
3.1 Global Erythropoietin Drugs Market Historical Value (2016-2022)
3.2 Global Erythropoietin Drugs Market Forecast Value (2023-2031)
4 Global Erythropoietin Drugs Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Erythropoietin Drugs Market Segmentation
5.1 Global Erythropoietin Drugs Market by Drug Type
5.1.1 Market Overview
5.1.2 Biologics
5.1.3 Biosimilars
5.2 Global Erythropoietin Drugs Market by Product Type
5.2.1 Market Overview
5.2.2 Epoetin-alfa
5.2.3 Epoetin-beta
5.2.4 Darbepoetin-alfa
5.2.5 Others
5.3 Global Erythropoietin Drugs Market by Application
5.3.1 Market Overview
5.3.2 Haematology
5.3.3 Kidney Disorder
5.3.4 Cancer
5.3.5 Others
5.4 Global Erythropoietin Drugs Market by End User
5.4.1 Market Overview
5.4.2 Hospitals
5.4.3 Homecare
5.4.4 Specialty Clinics
5.4.5 Others
5.5 Global Erythropoietin Drugs Market by Region
5.5.1 Market Overview
5.5.2 North America
5.5.3 Europe
5.5.4 Asia Pacific
5.5.5 Latin America
5.5.6 Middle East and Africa
6 North America Erythropoietin Drugs Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Erythropoietin Drugs Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Erythropoietin Drugs Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.5 ASEAN
8.6 Australia
8.7 Others
9 Latin America Erythropoietin Drugs Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Erythropoietin Drugs Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Regulatory Framework
11.1 Regulatory Overview
11.1.1 US FDA
11.1.2 EU EMA
11.1.3 INDIA CDSCO
11.1.4 JAPAN PMDA
11.1.5 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Amgen Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Biocon Limited
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Dr. Reddy’s Laboratories Ltd.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 F. Hoffmann-La Roche AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Intas Pharmaceuticals Ltd.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Johnson & Johnson
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 LG Chem Ltd.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Pfizer Inc.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Sun Pharmaceutical Industries Limited
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Teva Pharmaceutical Industries Ltd.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings